Discontinuation report PICATO
Report ID | 127361 |
Drug Identification Number | 02400995 |
Brand name | PICATO |
Common or Proper name | ingenol mebutate |
Company Name | LEO PHARMA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | INGENOL MEBUTATE |
Strength(s) | 0.05% |
Dosage form(s) | GEL |
Route of administration | TOPICAL TOPICAL |
Packaging size | 2 x 0.47g |
ATC code | D06BX |
ATC description | CHEMOTHERAPEUTICS FOR TOPICAL USE |
Reason for discontinuation | Other (Please describe in comments) |
Anticipated discontinuation date | |
Actual discontinuation date | 2020-10-14 |
Remaining supply date | 2020-12-11 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | On October 26, 2020, LEO Pharma Inc. initiated the recall of PICATO from the Canadian market. |
Company comments | On October 14, 2020, Health Canada directed LEO Pharma Inc. to stop the sale of PICATO at the manufacturer level. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 3389 STEELES AVENUE EAST, SUITE 110 TORONTO, ONTARIO CANADA M2H 3S8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2020-10-28 | French | Compare |
v1 | 2020-10-28 | English | Compare |
Showing 1 to 2 of 2